The ASX healthcare shares Goldman Sachs rates as a buy

Here are the ASX healthcare shares rated as buys from Goldman Sachs' 4th small/mid-cap healthcare forum this week.

| More on:
two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Goldman Sachs hosted its 4th small/mid-cap healthcare forum this week. This included 13 Australian and New Zealand healthcare companies across a diverse range of specialties. Here are the ASX healthcare shares that Goldman picked as a buy. 

Goldman's ASX healthcare shares to buy

Opthea Ltd (ASX: OPT

Opthea is developing a complementary medicine to be used with existing inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). 

Goldman believes there is multi-billion dollar potential in Opthea's treatment. The broker observes that existing treatments only inhibit up to two of the factors responsible for retinal disease, with over half of patients not achieving significant vision gains and a quarter experiencing continued vision loss. 

The company's lead candidate, OPT-302 is intended to complement existing treatments to produce an improved outcome for patients. 

Opthea successfully completed a A$169 million initial public offering on the US NASDAQ market in September 2020, improving its cash position to A$203 million in 1H21. Goldman believes this secures the company's funding for the completion of two pivotal Phase 3 trials. 

Pro Medicus Limited (ASX: PME

Within the context of medical imaging, Goldman believes that "globally, there is rapidly growing demand for solutions that can process, transfer and store this data efficiently, particularly given that speed and accuracy is intrinsically linked to treatment outcomes and commercial incentives".

Pro Medicus shares have been chugging along and up 33% year-to-date to a near all-time record high of $47.22.

Goldman has observed that its 3Q21 transaction volumes are tracking above pre-COVID levels with a strong backlog/deferral stream to provide growth for months to come.

Goldman has modelled "an average of 5 contract wins per year, at an average minimum size of A$15m pa, reflecting recent order momentum and our expectation of heightened interest in this technology through the coming periods ".

Integral Diagnostics Ltd (ASX: IDX

Integral Diagnostics is one of the largest diagnostic imaging companies in Australia.

Goldman observes that the company's 1H21 growth of 6.5% was softer than the 8.3% improvement from Medicare.

This was largely driven by Integral's geographical weighting in Victoria which was impacted by regional lockdowns. Looking ahead, the company has commented that volumes in the second half are growing in line with expectations. 

The growth drivers highlighted by Goldman and Integral include a "steady positive mix shift towards high-acuity imaging" and "Medicare reimbursement re-indexation from July-20 at c.+1.5% pa".

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia has recommended Integral Diagnostics Ltd and Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is rising on big FDA news

Some big news is giving this stock a major lift on Thursday.

Read more »